Aethlon ( (AEMD) ) has released its Q3 earnings. Here is a breakdown of the information Aethlon presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aethlon Medical, Inc., a company specializing in developing therapeutic products for cancer and infectious diseases, has announced its financial results for the fiscal third quarter ending December 31, 2024, along with recent corporate updates.
In its latest quarterly report, Aethlon Medical highlighted a significant milestone in its ongoing oncology trials in Australia, where the first patient was treated with the Hemopurifier. The company has also implemented strategic cost reductions, significantly decreasing its operating expenses.
The company’s financial performance for the quarter showed a reduction in operating expenses by 50% compared to the previous year, driven by decreases in payroll and professional fees. The net loss also decreased to $1.8 million from $3.5 million the previous year. Aethlon continues to focus resources on its oncology trials in Australia and India, with the recent protocol amendments expected to enhance trial efficiency and patient enrollment.
Looking ahead, Aethlon Medical is poised to advance its clinical trials and maintain its focus on resource optimization. The management expects that the ongoing studies will provide valuable insights for future oncology efficacy trials, while continuing to monitor developments in infectious diseases globally.